GHO Capital is buying NaviMed Capital’s Velocity Clinical Research, which after proving its ability to meet the unprecedented needs fueled by covid-19 is prepared to ramp up further as the landscape evolves.
GHO Capital buys Velocity Clinical Research for about $500m
Covid has accelerated Velocity's growth plan by one to two years, while illustrating the clinical site organization's ability to efficiently ramp up operations, adapting to the needs of CROs and patients.
